Cellectar Biosciences Inc. Common Stock (CLRB)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor in the Graham and Buffett tradition, so I start with earnings and a margin of safety. Cellectar is a clinical-stage biopharmaceutical company with no reported revenue in any of the filed periods shown. Its lead asset, iopofosine I-131, is in Phase 2 studies for B-cell malignancies. The income statement shows a fiscal 2025 net loss of $21.8 million and diluted EPS of -$8.35; FY2024 net loss was $44.6 million, and FY2023 was $42.8 million. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, it lost $6.9 million, or -$0.57 per diluted share. Trailing free cash flow is -$19.5 million. Against a $13.1 million market cap at the 2026-10-13 close, that is a FairStock-calculated FCF yield of -148.3%, meaning the enterprise is burning cash far faster than its market value. The balance sheet has low leverage—D/E 0.05—but the Piotroski F-Score of 2/9 and Altman Z-Score of -8.63 are distress signals. FairStock-calculated ROE is -119.57% and ROCE is -58.44%, confirming capital destruction. Book value looks cheap at P/B 0.38, but for a loss-making biotech, book value may not be a durable margin of safety because the company has no revenue and is burning cash. A P/E of -0.63 simply reflects negative earnings. There is no evident moat; value depends on trial outcomes. Growth is not revenue growth—it is cash burn. I would call this a speculative option on science, not a value investment.

In plain English: Cellectar Biosciences is a very small company trying to develop a cancer drug called iopofosine I-131. It has no reported sales and has been losing money, so the business looks financially weak and depends heavily on whether the drug works in testing. At $1.39, the price may look low compared with its accounting value, but because there are no sales and large losses, it is not a stable bargain—it is a high-risk situation.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer